stockrow
Friday 6 November 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
24.58
1.45
−5.57%
Follow CAI
Alert me
Caris Life Sciences,�Inc. (CAI) Net income
Caris Life Sciences,�Inc.'s net income for fiscal 2025 was −$68.1M, compared with −$281.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was $96.1M. Caris Life Sciences,�Inc. ranks 31st of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$68.1M | — |
| FY2024 | −$281.9M | — |
| FY2023 | −$341.4M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $15.3M | — |
| Jun 2026 | −$637.0K | — |
| Mar 2026 | −$510.0K | — |
| Dec 2025 | $82.0M | 236.92% |
| 6 more quarters | Free account |
Net income against peers
| Company | Net income |
|---|---|
| TGTX TG Therapeutics, Inc. compare | $441.5M |
| KRYS Krystal Biotech, Inc. compare | $225.2M |
| CAI Caris Life Sciences,�Inc. | $96.1M |
| PTGX Protagonist Therapeutics, Inc. compare | $82.9M |
| TWST Twist Bioscience Corporation compare | −$136.7M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$155.5M |
| SYRE Spyre Therapeutics, Inc. compare | −$263.9M |
| CYTK Cytokinetics, Incorporated compare | −$777.9M |
| IBRX ImmunityBio, Inc. compare | −$992.4M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on CAI
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement